1/88
Looks like no tags are added yet.
two to four
- triple therapy for maintenance phase: corticosteroid, CNI, anti-proliferative
Generally, patients receive a combination of ____ immunosuppressive drugs in order to minimize individual drug toxicities as well as block different pathways of the immune response
Calcineurin inhibitors (CNI): tacrolimus and cyclosporine
____ are the most commonly used immunosuppressive regimens, but they are associated with serious adverse effects
nephrotoxicity
Calcineurin inhibitor-induced ____ is one of the most common adverse effects observed in solid-organ transplant recipients
Corticosteroids
____ are first-line treatment for allograft rejection
Bone marrow suppression
Azathioprine and mycophenolic acid derivatives inhibit T-cell proliferation by altering purine synthesis. ____ is the most significant adverse effect associated with these agents.
cardiac transplantation
Treatment of choice for patients with severe end-stage heart failure.
- Candidates generally present with NYHA class III or IV symptoms and EF <20%
- General indications: rapidly declining cardiac function, requirement of IV inotropes, and a projected 1-year mortality rate of greater than 75%
General presentation and indications for cardiac transplantation
- Acute hepatic necrosis: chronic or acute hepatitis B or C
- Neoplasms: hepatoma, cholangiocarcinoma
Indications for liver transplantation
- may involve the use of the entire organ or a segment
- Cystic fibrosis, emphysema/chronic obstructive pulmonary disease
Indications for lung transplantation
- may involve deceased donation of two lungs or a single lung
DM, glomerular diseases (Goodpasture syndrome), hypertension, neoplasm (ie, renal cell carcinoma), polycystic kidney disease
Indications for kidney transplantation
true, if they are healthy enough to undergo surgery
- 700,000+ patients are living with ESRD in the US today
T/F: All patients with ESRD should be considered for renal transplantation.
Autograft
- antigen present in autograft is the same as that present in body (skin), so the immune system recognizes the autograft antigen as a self antigen and no immune response is elicited.
Self-tissue is transferred from one body site to another
Syngeneic graft (isograft)
- no immune response is elicited
Grafts transplanted between two genetically identical individuals of the same species (twins)
Allograft
- An immune response is elicited
Grafts between members of the same species genetically different; most common form
Xenograft
- An immune response is elicited
Tissue or organs from an individual of one species transplanted into or grafted onto an organism of another species (ex: pig heart valve)
Hyperacute rejection
- uncommon due to routine pretransplant surveillance testing
Rejection that may be evident within minutes of the transplantation procedure when preformed donor-specific antibodies are present in the recipient at the time of the transplant
- Ischemic damage to the microvasculature rapidly results in tissue necrosis
- Organ must be removed immediately to prevent severe systemic responses
Acute cellular rejection
Rejection that usually occurs in the first few months following transplantation, but can occur at any time during the life of the allograft
T-lymphocytes
Acute cellular rejection is mediated by alloreactive ____ that appear in the circulation and infiltrate the allograft through the vascular endothelium
- cytotoxic cells specifically target and kill the functioning cells in the allograft
30%
Acute cellular rejection of a kidney transplant can affect up to 20% of patients during the first 6 months following transplantation. Rejection is evidenced by an abrupt rise in serum creatinine concentration ≥____% over baseline.
1. High-dose steroids (pulse with subsequent taper)
- Three daily intravenous pulses of 500, 250, and 250 mg methylprednisolone intraoperatively and on postoperative days 1 and 2
- Taper CS dose to 20 mg oral methylprednisolone per day for 2-4 wk following transplant.
2. Addition of another immunosuppressant indefinitely
3. Short-term treatment with a polyclonal or monoclonal antibody
Treatment of acute cellular rejection post-transplant
Humoral rejection
Rejection characterized by the presence of antibodies directed against HLA antigens present on the donor vascular endothelium
Acute antibody-mediated rejection
- Less common than cell-mediated rejection
Type of rejection in which antibodies activate complement, creating a membrane attack complex that directly damages the organ and attracts inflammatory cells to the allograft
- Damage is distinct from cellular rejection and involves microvascular injury, often to the peritubular capillaries
- Usually occurs in the first 3 months after transplantation
- Associated with an increased fatality rate
Chronic rejection
Major cause of graft-loss; occurs ≥1 year post-transplant; slow, insidious form of acute rejection, resulting in worsening organ function over time
HTN, proteinuria, and progressive decline in kidney function
What is the classic triad of chronic allograft nephropathy?
Retransplantation
What is the only effective treatment option for chronic rejection?
Induction therapy
Provides a high level of immunosuppression in the early posttransplant period, when the risk of acute rejection is highest; given before or at the time of transplant to prevent acute rejection
Maintenance immunosuppression
Prevent acute and chronic rejection while minimizing drug-related toxicity
1. Non-depleting agent: Basiliximab (Simulect)
2. Depleting agents:
- Polyclonal antibodies: antithrombocyte globulin rabbit and equine
- Monoclonal antibodies: Alemtuzumab (Compath)
Induction agents
Antithymocyte globulin IV for 5-10 days for induction
- Atgam: equine polyclonal antibody
- Thymoglobulin: rabbit polyclonal antibody (less immunogenic, more potent)
Depleting antibody used as an induction agent and is also approved for corticosteroid-resistant rejection
1. Infusion-related reactions: fever, chills, pruritus, hypotension
- pretreat with Diphenhydramine, Acetaminophen, and corticosteroids
2. Dose-limiting myelosuppression
3. Infections
4. Malignancy
SEs of Antithymocyte globulin (Atgam, Thymoglobulin)
Administer under the supervision of a physician experienced in immunosuppressive therapy. Supportive medical resources (epinephrine) must be readily available. Anaphylaxis can occur.
BBW for Antithymocyte globulin (Atgam, Thymoglobulin)
Alemtuzumab (Compath)
Depleting antibody that is commonly used for treatment of acute rejection and induction (not FDA-approved uses)
- FDA-approved for B-cell chronic lymphocytic leukemia
- Humanized mab against CD52 surface antigen found on T and B lymphocytes
Neutropenia, thrombocytopenia, anemia, n/v/d, HA, dizziness
SEs of Alemtuzumab (Compath)
Basiliximab (Simulect) given 2 hours prior to transplant, followed by a dose on post-op days 2 and 4
Non-depleting IL-2 receptor antagonist that is the most commonly used induction drug
HTN, fever, stomach upset, n/v, edema, dyspnea, tremor
SEs of Basiliximab (Simulect)
Use only by physicians experienced in immunosuppressive therapy
BBW on Basiliximab (Simulect)
Calcineurin Inhibitors: Tacrolimus and Cyclosporine
Which class of medication is first-line for maintenance therapy post-transplant?
protein
Both calcineurin inhibitors are highly ___ bound
3A4 and P-gp
The calcineurin inhibitors are extensively metabolized by:
82%
Diltiazem, Verapamil, and Erythromycin (inhibitors) can increase the concentration of the calcineurin inhibitors by ____%
50%
Phenytoin and Rifampin (inducers) can decrease the concentration of the calcineurin inhibitors by ____%
nephrotoxicity
Major disadvantage of the calcineurin inhibitors
1. Delaying administration immediately post-op in patients at risk for nephrotoxicity (using an IL-2 Receptor Antagonist or Antilymphocyte globulin)
2. Monitoring trough blood concentrations
3. Reducing the dose
4. Avoiding other nephrotoxins: aminoglycosides, amphotericin B, NSAIDs
Ways to reduce nephrotoxicity with the calcineurin inhibitors:
Tacrolimus
- Prograf: IR capsule BID dosing; oral packet; IV injection
- Astagraf XL capsules: take every morning on an empty stomach (1-2 hours after a meal)
- Envarsus XR tablets: take once daily in the morning
First-line medication for maintenance post-transplant
1. Astagraf XL: Increased mortality in female liver transplant patients
2. Malignancy and serious infections
BBWs for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)
SEs
- HTN
- Hyperglycemia (post-transplant diabetes)
- Neurotoxicity: tremor, HA, dizziness, seizures
- Nephrotoxicity (less than Cyclosporine
- QT prolongation
- Edema
- Insomnia
- Chest pain
- Diarrhea
- Anemia, leukopenia, thrombocytopenia
- Alopecia
- Infections
Monitoring: CBC, SCr, BUN, BP, BG, lipids, trough
SEs and monitoring parameters for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)
5-12 ng/ml
Trough level for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)
Sandimmune (non-modified)
- capsule, oral solution, IV injection (1/3 of PO dose)
Cyclosporine formulation with significant variability in absorption; mixes poorly with GI fluids, causing low and inconsistent absorption
Neoral, Gengraf
- capsule, oral solution
Modified cyclosporine microemulsion formulations that have higher and more consistent absorption
True, they cannot be used interchangeably.
T/F: Neoral/Gengraf (cyclosporine modified) and Sandimmune (cyclosporine non-modified) are not bioequivalent.
100-400 ng/ml
(nephrotoxicity can occur at any level)
Trough level for Cyclosporine (Sandimmune, Neoral, Gengraf)
SEs:
- HTN (more than Tacrolimus)
- Hyperkalemia, Hypomagnesemia
- Hirsutism
- Gingival hyperplasia
- Increased triglycerides
- QT prolongation
- Viral infections
- Anemia, Leukopenia, Thrombocytopenia
Monitoring: trough levels, serum electrolytes, CBC, renal function, LFTs, BP, lipid profile
SEs and monitoring parameters for Cyclosporine (Sandimmune, Neoral, Gengraf)
1. Hypertension and Nephrotoxicity
2. Immunosuppression: increased risk of lymphoma and other malignancies (skin cancer)
3. Experienced physician: only health care providers experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe cyclosporine
4. Bioavailability: Sandimmune capsules and oral solution have decreased bioavailability in comparison with Gengraf and Neoral capsules and Gengraf and Neoral oral solution
BBWs on Cyclosporine (Sandimmune, Neoral, Gengraf)
Azathioprine (Imuran)
- tablets, IV
Antimetabolite, antiproliferative agent that is a prodrug of 6-mercaptopurine and inhibits T-lymphocyte proliferation by altering purine synthesis
- used in maintenance therapy as an alternative to Mycophenolate mofetil
Dose-limiting: leukopenia, anemia, thrombocytopenia
- occur within the first few weeks of therapy; can be managed by a dose reduction of AZA or discontinuation
Other SEs:
- N/v (take with food)
- Alopecia
- Hepatotoxicity
- Pancreatitis
SEs of Azathioprine (Imuran)
Increased risk of malignancy and hematologic toxicities
BBW on Azathioprine (Imuran)
Xanthine oxidase inhibitors: Allopurinol, Feboxustat
_____ can increase Azathioprine (Imuran) and 6-MP concentrations by four-fold if administered together; reduce the dose of AZA by 50-75% when used concurrently.
Mycophenolate mofetil
- Cellcept: tablet, capsule, suspension, IV injection
- Myfortic: enteric-coated tablets (reduces GI upset)
First-line antiproliferative (antimetabolite) agent for maintenance immunosuppression in solid organ transplantation
Most common: GI upset → n/v/d, abdominal pain
Other SEs: bone marrow suppression, edema
Monitoring: CBC, intolerable diarrhea, SCr, LFTs, signs of infection
SEs and monitoring parameters for Mycophenolate mofetil (Cellcept, Myfortic)
1. Experienced physician (Myfortic): only healthcare providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Mycophenolate
2. Serious infections
3. Malignancies
4. Embryo-fetal toxicity: use during pregnancy is associated with increased risks of first-trimester pregnancy loss and congenital malformations
- The REMS program recommends discontinuing mycophenolate in females at least 6 weeks before pregnancy is attempted
BBWs on Mycophenolate mofetil (Cellcept, Myfortic)
1. Aluminum and magnesium-containing antacids
2. Cholestyramine
3. PPIs decrease levels of Mycophenolate
DDIs with Mycophenolate mofetil (Cellcept, Myfortic)
light
- dispense in a light-resistant container
Mycophenolate mofetil (Cellcept, Myfortic) tablets must be protected from ____.
D5W
Cellcept (IV) is only stable in _____
Mamalian Target of Rapamycin (mTOR) Inhibitors
1. Everolimus (Zortress): DOC
- improved PKs, shorter half-life, steady state is reached faster
- tablets
- NO loading dose necessary
2. Sirolumus (Rapamune)
- tablets, oral solution
- loading dose recommended
Class of medications that can be used in place of Calcineurin Inhibitors to lower the risk of nephrotoxicity or can be used concurrently with CNIs instead of an antiproliferative
CYP3A4 and P-gp
The mTOR inhibitors are extensively metabolized by:
3 months
The mTOR inhibitors cause delayed wound healing (more with Sirolimus); start these drugs ____ months after transplantation.
Hyperlipidemia; Pravastatin is the DOC due to no DDIs
What is a major side effect of the mTOR inhibitors? How is it managed?
Most common: leukopenia, thrombocytopenia, hyperlipidemia
Other: anemia, diarrhea, arthralgias, rash, HTN, proteinuria, pneumonitis (more common with Sirolimus; d/c if this develops), stomatitis, nephrotoxicity (more with Sirolimus), angioedema (especially with an ACEi), hyperglycemia (Everolimus)
SEs of the mTOR inhibitors
1. Immunosuppression: infection, malignancy (lymphoma, skin cancer)
2. Kidney graft thrombosis: increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days post-transplantation
3. Nephrotoxicity: can occur with the use of standard doses of cyclosporine in combination with everolimus; reduce dose of cyclosporine when used in combination with everolimus
4. Mortality in heart transplant: use in heart transplantation is not recommended.
BBWs on Everolimus (Zortress)
1. Immunosuppression: infection, malignancy (lymphoma)
2. Use is not recommended in lung and liver transplantation
3. Experienced physician
BBWs on Sirolimus (Rapamune)
Methylprednisolone and Prednisone
- High-dose IV methylprednisolone (250-1000 mg) is given at the time of transplantation, and the dose is tapered rapidly and usually discontinued within 3-5 days when oral prednisone is initiated. Taper over several weeks to months
Corticosteroids are the cornerstone of immunosuppression regimens. 30% of liver and 60% of kidney transplant patients receive corticosteroids for at least the first year after transplantation. What are the most commonly used corticosteroids?
Belatacept (Nulojix) IV infusion monthly
- requires access to an infusion center or a home infusion service to ensure appropriate administration
Co-stimulatory signal inhibitor that is the first IV biological maintenance immunosuppressive agent in renal transplant patients only
- may be used in place of CNIs
- Infections: UTI, URTI
- GI upset: nv/d/c
- Hyper or hypokalemia
- HA
- Peripheral edema
- Anemia, leukopenia
- Hypotension
- Arthralgia
- Insomnia
SEs of Belatacept (Nulojix)
Increased risk for serious infections, malignancies, and post-transplant lymphoproliferative disorder, with the highest risk in EBV-naive patients
- use only in EBV seropositive patients
BBW on Belatacept (Nulojix)
DHP CCBs: Amlodipine or Felodipine
- Goal BP in all renal transplant patients: <130/80
Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Hypertension can be caused by corticosteroid use, use of cyclosporine or tacrolimus, and impaired kidney graft function. What is the preferred antihypertensive in transplant patients? What is the goal BP?
cholesterol >200 mg/dL
TG > 350 mg/dL
Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Dyslipidemia can be caused by the use of corticosteroids, CNIs, and mTOR inhibitors. The risk of IHD is doubled with serum cholesterol >___ mg/dL or TGs >____ mg/dL
Pravastatin
- no interactions because it is not metabolized by CYP3A4
- monitor for rhabdo and increased LFTs
Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Dyslipidemia can be caused by the use of corticosteroids, CNIs, and mTOR inhibitors. What is the drug of choice for dyslipidemia in transplant patients?
- More than 40% will require insulin
- Oral agent: Glipizide
- Use Metformin with caution due to the risk of lactic acidosis in those with impaired kidney function
Corticosteroids and CNIs (Tacrolimus) can impair glucose control in patients with pre-existing diabetes and can also cause new-onset diabetes after transplantation in 5-30% of patients. Other risk factors for diabetes include: AA or Hispanic ethnicity, age >40 at time of transplant, family history, and weight. What is the preferred treatment for diabetes in post-transplant patients?
opportunistic
- Pneumocystis jirovecii pneumonia
- Cytomegalovirus
Prophylactic therapy for ____ infections is started in all transplant patients.
6 months
Prophylactic therapy for Pneumocystis jirovecii pneumonia is continued for ____ months after transplant.
Bactrim DS once daily
- continued for 6-12 months after transplant
- monitor for myelosuppression, nephrotoxicity, rash, and photosensitivity
- alternatives: Dapsone, Atovaquone
DOC for Pneumocystis jirovecii pneumonia prophylaxis
3-6 months
Prophylactic therapy for cytomegalovirus usually occurs within the first ____ months post-transplantation.
200 days (can be used for longer)
Prophylactic therapy for cytomegalovirus usually occurs within the first 3-6 months post-transplantation and continued for the first ____ days.
1. Valganciclovir (Valcyte) 450-900 mg PO QD
2. Ganciclovir (Cytovene) 5 mg/kg IV daily
DOC for cytomegalovirus prophylaxis
Polyomavirus-associated
_____-associated nephropathy is an important case of impaired kidney function in kidney transplant recipients; it is caused by the BK virus that is reactivated in immunocompromised patients.
BK virus
Patients should be screened for urinary ____ virus replication montly for the first 3-6 months after transplant, and every 3 months thereafter for the first year.
Reduce immunosuppressive medications/doses or add Cidofovir
First-line treatment for the polyoma virus
skin cancer
Most common type of cancer in transplant patients
kidney
The risk of lung and colon cancers is nearly doubled in ____ transplant recipients.